Please login to the form below

Not currently logged in
Email:
Password:

Pharma firms in biotech cluster

Roche, Merck Serono and Abbott are to join forces in the development of the Biotechnology Cluster Rhine-Neckar, one of the leading life science clusters in Europe

Roche, Merck Serono and Abbott are to join forces in the development of the Biotechnology Cluster Rhine-Neckar (BioRN), one of the leading life science clusters in Europe.

The BioRN cluster focuses on the development of innovative drugs, diagnostics and technologies in cell-based and molecular medicine. "The success of the BioRN cluster, which brings together some 100 partners in business and research, rests partly on the excellent pioneering research being done here in the Rhine-Neckar region and on the presence of several major corporations, many of them global leaders in their field such as Roche, Merck Serono and Abbott," said Dr Jürgen Schwiezer, CEO of the Roche diagnostics division.

Roche and Merck Serono, along with small biotech companies and major research institutions, already participate in BioRN cluster activities. As well as developing drugs and diagnostics, the cluster runs special education programmes for life scientists, managers and entrepreneurs.

Speaking about the collaboration, Dr Bernhard Kirschbaum, executive vice president, research and development, at Merck Serono, said: "The strong network that is now formed in the Rhine-Neckar region will lead to the faster translation of technological advances and market intelligence into competitive advantage and ultimately benefits for patients."

The companies made the announcement at the annual BIO-Europe partnering event.

17th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics